Ascletis first to file biotech IPO under new HK regime

By John Loh
08 May 2018

China's Ascletis Pharma has emerged as the first biotechnology firm to test the waters of Hong Kong’s new listing regime, after filing a draft prospectus on Monday.

Morgan Stanley is left lead on the IPO and a sponsor alongside China Merchants Securities and Goldman Sachs. The filing comes a week after the Hong Kong bourse amended its rules to allow listings of pre-revenue biotech companies, as well as allowing weighted voting rights.

The issuer ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial